Xynomic Pharmaceuticals, Inc.

ACTIVE

3500 S Dupont Hwy Ste SS101, 加利福尼亚州圣迭戈县, California, United Stateswww.xynomicpharma.comSubsidiary

Part of bison capital acquisition corp.

Clinical Trials

10 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

66.7%

Phase 2

25.0%

Phase 3

8.3%

Trial Status Distribution

Active, not recruiting

75.0%

Not yet recruiting

8.3%

Recruiting

16.7%

Clinical Trials

Trials sponsored by this organization (12)

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation

Phase 1

Not yet recruiting

interventional

Dec 2025221 participants

A phase 2 clinical trial designed to investigate the safety and effectiveness of the investigational product Abexinostat, in patients with relapsed or refractory Follicular Lymphoma.All subjects will receive the study drug Abexinostat.

Phase 1

Active, not recruiting

Nov 2020139 participants

A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Phase 1

Active, not recruiting

Nov 2020413 participants

A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

Phase 2

Active, not recruiting

interventional

Apr 202087 participants

Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2

Recruiting

interventional

Jan 2020170 participants

A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients

Phase 1

Active, not recruiting

interventional

Jan 202012 participants

A phase 2 clinical trial designed to investigate the safety and effectiveness of the investigational product Abexinostat, in patients with relapsed or refractory Follicular Lymphoma.All subjects will receive the study drug Abexinostat.

Phase 1

Active, not recruiting

Feb 2019139 participants

A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Phase 1

Active, not recruiting

Jan 2019413 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations